Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/202134
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | López Campos, Fernando | - |
dc.contributor.author | Gajate, Pablo | - |
dc.contributor.author | Romero Laorden, Nuria | - |
dc.contributor.author | Zafra Martín, Juan | - |
dc.contributor.author | Juan, Manel | - |
dc.contributor.author | Hernando Polo, Susana | - |
dc.contributor.author | Conde Moreno, Antonio | - |
dc.contributor.author | Couñago, Felipe | - |
dc.date.accessioned | 2023-09-21T12:37:30Z | - |
dc.date.available | 2023-09-21T12:37:30Z | - |
dc.date.issued | 2022-02-24 | - |
dc.identifier.issn | 2227-9059 | - |
dc.identifier.uri | http://hdl.handle.net/2445/202134 | - |
dc.description.abstract | The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular biomarkers that could predict response to immunotherapy represents one of the current challenges in this clinical scenario. The management of advanced castrationresistant prostate cancer is rapidly evolving and immunotherapy treatments, mostly consisting of immune checkpoint inhibitors combinations, BiTE (R) (bispecific T-cell engager) immune therapies, and chimeric antigen receptors (CAR) are in development with promising results. This review analyses the current evidence of immunotherapy treatments for mCRPC, evaluating past failures and promising approaches and discussing the directions for future research. | - |
dc.format.extent | 18 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/biomedicines10030537 | - |
dc.relation.ispartof | Biomedicines, 2022, vol. 10, num. 3 | - |
dc.relation.uri | https://doi.org/10.3390/biomedicines10030537 | - |
dc.rights | cc by (c) López Campos, Fernando et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Càncer de pròstata | - |
dc.subject.classification | Immunoteràpia | - |
dc.subject.other | Prostate cancer | - |
dc.subject.other | Immunotheraphy | - |
dc.title | Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-07-06T14:25:15Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9308040 | - |
dc.identifier.pmid | 35327339 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Immunotherapy in Advanced Prostate Cancer Current Knowledge and Future Directions_Biomedicines.pdf | 1.15 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License